Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prelude Therapeutics IncPRLD · Entity 5561 | Chief Chemistry Officer | February 04, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prelude Therapeutics Inc
Report date February 04, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2036-02-03 | Direct | 230,000 |
Reported balance
After 2026-02-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 230,000 · Balance 230,000 F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2026 Filed Feb 5, 2026 21:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001825005-26-000002 · primarydocument.xml · derivative · entry 1 Combs Andrew · CIK 0001825005 · Chief Chemistry Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 20:40 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 100,000 | $0.69 | $69,250.00 |
DisclosureSEC source: 0001562180-25-002779 · primarydocument.xml · nonDerivative · entry 1 Combs Andrew · CIK 0001825005 · Chief Chemistry Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,123 F1 · balance_after: The reported total includes 2,500 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c). Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:32 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001562180-25-000957 · primarydocument.xml · derivative · entry 1 Combs Andrew · CIK 0001825005 · Chief Chemistry Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 12:49 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 60,000 | $1.37 | $82,002.00 |
DisclosureSEC source: 0001562180-24-008565 · primarydocument.xml · nonDerivative · entry 2 Combs Andrew · CIK 0001825005 · Chief Chemistry Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,623 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 12:49 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 3,075 | $1.15 | $3,536.25 |
DisclosureSEC source: 0001562180-24-008565 · primarydocument.xml · nonDerivative · entry 1 Combs Andrew · CIK 0001825005 · Chief Chemistry Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,623 F1 · balance_after: The reported total includes 10,106 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c). Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 23:05 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001562180-24-002136 · primarydocument.xml · derivative · entry 1 Combs Andrew · CIK 0001825005 · Chief Chemistry Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:08 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-23-001169 · primarydocument.xml · derivative · entry 1 Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-02-06 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 21:08 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 36,062 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-22-022524 · doc4.xml · derivative · entry 2 Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,397 Underlying: Common Stock · 36,062 shares Expires 2030-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:08 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | Exercise / conversionCommon Stock | 36,062 | $1.89 | $68,157.18 |
DisclosureSEC source: 0001209191-22-022524 · doc4.xml · nonDerivative · entry 1 Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.58 | $0.00 |
DisclosureSEC source: 0001209191-22-011031 · doc4.xml · derivative · entry 1 Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 22:21 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 4,000 | $11.60 | $46,400.00 |
DisclosureSEC source: 0001209191-21-069796 · doc4.xml · nonDerivative · entry 2 Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,380 F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 22:21 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 4,000 | $12.12 | $48,480.00 |
DisclosureSEC source: 0001209191-21-069796 · doc4.xml · nonDerivative · entry 1 Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,380 F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 22:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $31.23 | $0.00 |
DisclosureSEC source: 0001209191-21-047831 · doc4.xml · derivative · entry 1 Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2031-07-19 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:11 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 1,000 | $19.00 | $19,000.00 |
DisclosureSEC source: 0001209191-20-052405 · doc4.xml · nonDerivative · entry 1 Combs Andrew · CIK 0001825005 · EVP, Head of Chemistry 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,380 F1 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.